Patent application number | Description | Published |
20100047342 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-25-2010 |
20100260838 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 10-14-2010 |
20100266684 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 10-21-2010 |
20110059169 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 03-10-2011 |
20120045508 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-23-2012 |
20120046365 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-23-2012 |
20120058182 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 03-08-2012 |
20130165517 | Composition and Method for Treating Neurological Disease - A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine. | 06-27-2013 |
20130317115 | Composition and Method for Treating Neurological Disease - A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day. | 11-28-2013 |
20140127224 | Therapeutic Method - Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome. | 05-08-2014 |
20140179797 | Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject. | 06-26-2014 |
20140323582 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day. | 10-30-2014 |
20140343152 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343153 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343154 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343163 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140343164 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 11-20-2014 |
20140356425 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 12-04-2014 |
20150086483 | METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS - The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided. | 03-26-2015 |